What's Happening?
Jing Cheong Asia Inc., operating as New York Tong Ren Tang, has received a warning letter from the FDA dated October 26, 2026. The FDA identified three unapproved new drugs being marketed through the company's e-commerce website: 'Ofloxacin Eye Drops,'
'Jingzhi Niuhuang Jiedu Pian,' and 'Gui Pi Wan.' The agency flagged the ophthalmic product, Ofloxacin Eye Drops, as the most significant public health concern due to its intended use for bacterial conjunctivitis, keratitis, corneal ulcers, dacryocystitis, and post-operative ocular infections, which require sterility assurance and regulatory approval. The other two products, traditional Chinese medicines, made therapeutic claims for conditions like aplastic anemia, thrombocytopenic purpura, measles, and mumps. These claims classify the products as drugs under the Federal Food, Drug, and Cosmetic Act, requiring FDA approval that they lack. The violations were discovered during a website review in September 2026.
Why It's Important?
This FDA action highlights the agency's continued online surveillance program and its commitment to regulating products marketed with therapeutic claims, regardless of their traditional or heritage formulations. The marketing of unapproved drugs, especially those for ophthalmic use, poses significant public health risks as their safety, efficacy, and quality are not assured. Consumers using such products may experience adverse effects or delay seeking appropriate medical treatment. For legitimate manufacturers and distributors, this serves as a reminder to meticulously audit website content against FDA labeling standards (21 CFR Part 201) to ensure no product carries therapeutic claims without corresponding approved applications or recognized exemptions. The FDA's explicit note that the listed violations are not exhaustive indicates a broader enforcement effort against non-compliant online drug sales.
What's Next?
New York Tong Ren Tang is expected to respond to the FDA's warning letter. Failure to adequately address the identified violations could lead to further regulatory or legal actions, including seizure of products or injunctions, without additional notice. The FDA's reference number 738200 will be used to measure the company's corrective response. This enforcement action also signals to other companies distributing products through online channels, particularly those with traditional formulations, that they should proactively review their marketing practices and product claims to ensure compliance with FDA regulations. The FDA's ongoing surveillance suggests that similar actions against other non-compliant entities are possible.
Beyond the Headlines
The FDA's focus on online marketing and therapeutic claims for traditional medicines underscores a broader challenge in a globalized marketplace where products from diverse health traditions are sold to U.S. consumers. The case of New York Tong Ren Tang illustrates the tension between traditional health practices and modern regulatory frameworks designed to ensure public safety and product efficacy. This incident could lead to increased scrutiny of online retailers selling products with health claims, potentially impacting the availability of certain traditional remedies in the U.S. market. It also raises questions about consumer awareness regarding the regulatory status of products purchased online and the potential risks associated with unapproved treatments.
